Iovance Biotherapeutics Inc. (IOVA)
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 12.87 -0.35%
IOVA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.85B
- EPS (TTM)
- -$0.69
- Dividend yield
- None
- 52-week range
- 1.76 – 15.30
- Day range
- 12.31 – 13.15
- Volume / Avg
- 14.52M / 17.73M
- Beta
- —
- Shares outstanding
- 452.97M
- Next earnings
- Nov 5, 2026
52-week range
IOVA stock today
Shares of Iovance Biotherapeutics (IOVA) finished lower on Oct 7 at $12.92, a drop of 0.35% or $0.045 per share, versus the S&P 500's 0.22% decline. Shares are 15.6% below their 52-week high of $15.30, set on Sep 29, 2026 and 633.8% above the 52-week low of $1.76, near the top of the past year's range. IOVA is up 373.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 492.4%.
Iovance Biotherapeutics has posted a net loss over the last twelve months (EPS of -$0.69), so its P/E ratio is not meaningful. Iovance Biotherapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Iovance Biotherapeutics
Company profileIovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Frederick G. Vogt Esq., J.D., Ph.D.
- Headquarters
- San Carlos, CA
- Employees
- 975
- Website
- iovance.com
Financial highlights
Full financialsIn fiscal 2025, Iovance Biotherapeutics generated $263.5 million in revenue, up 60.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Iovance Biotherapeutics reported a net loss of $391.0 million, compared with a loss of $372.2 million a year earlier. Gross margin was 34.3% (down from 43.2%) and operating margin -153.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $263.50M | $164.07M | $1.19M | — | — |
| Growth | +60.60% | +13698.99% | — | — | — |
| Net income | $-390.98M | $-372.18M | $-444.04M | $-395.89M | $-342.25M |
| EPS (diluted) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$12.80-0.89%
- Strong buy 2
- Buy 6
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.09
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.11 vs —
IOVA news
All IOVA newsIovance Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs IOVA |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs IOVA |
| SRRKScholar Rock Holding Corporation | 42.20 | -0.59% | $5.14B | vs IOVA |
| IMVTImmunovant Inc. | 32.04 | -0.22% | $6.62B | vs IOVA |
| CRSPCRISPR Therapeutics AG | 52.35 | -3.06% | $5.06B | vs IOVA |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs IOVA |
| RLAYRelay Therapeutics Inc. | 17.95 | -4.22% | $3.93B | vs IOVA |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs IOVA |
Indexes, lists and sector
Iovance Biotherapeutics stock FAQ
What is Iovance Biotherapeutics's stock price today?
IOVA last traded at $12.92 as of Oct 7, 4:00 PM EDT, down 0.35% on the day. Prices are delayed at least 15 minutes.
Does Iovance Biotherapeutics pay a dividend?
No. Iovance Biotherapeutics does not currently pay a regular cash dividend.
When is Iovance Biotherapeutics's next earnings date?
Iovance Biotherapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.09.
Who is Iovance Biotherapeutics's CEO?
Dr. Frederick G. Vogt Esq., J.D., Ph.D. is the chief executive officer of Iovance Biotherapeutics Inc., which has about 975 employees.
Has IOVA ever split its stock?
Yes. The most recent IOVA stock split was a 1-for-100 split on Sep 26, 2013.
What is the IOVA 52-week high?
The 52-week high for IOVA is $15.30 and the 52-week low is $1.76. The stock is currently 15.6% below its high.